EOMA Cells
CAD$545.10*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The EOMA cell line, also known as EOMA endothelial cells, is derived from a spontaneously arising hemangioendothelioma in a mouse. This cell line is extensively used in research to study angiogenesis, the process of new blood vessel formation, which is critical in both normal physiological processes and in pathological conditions such as cancer, diabetic retinopathy, and rheumatoid arthritis. EOMA cells are characterized by their endothelial origin, displaying properties typical of endothelial cells, including the formation of capillary-like structures in vitro. Researchers utilize the EOMA cell line to investigate the molecular and cellular mechanisms underlying angiogenesis. This includes studies on the role of various growth factors, signaling pathways, and the extracellular matrix in endothelial cell proliferation, migration, and tube formation. EOMA cells are particularly valuable in evaluating the effects of anti-angiogenic compounds, which are used in the treatment of cancer and other diseases involving abnormal blood vessel growth. These cells are also used in gene expression studies and in the development of therapeutic strategies targeting angiogenesis. In addition to angiogenesis research, EOMA cells serve as a model for studying hemangioendothelioma, a rare vascular tumor, providing insights into tumor biology and the identification of potential therapeutic targets. By offering a reliable and reproducible in vitro system, the EOMA cell line significantly contributes to the understanding of vascular biology and the development of treatments for angiogenesis-related diseases. |
|---|---|
| Organism | Mouse |
| Tissue | Blood vessel |
| Disease | Hemangioendothelioma of the mouse blood vessel, malignant |
Characteristics
| Breed/Subspecies | 129 |
|---|---|
| Age | Adult |
| Gender | Unspecified |
| Morphology | Endothelial |
| Cell type | Endothelial cell |
| Growth properties | Adherent |
Regulatory Data
| Citation | EOMA (Cytion catalog number 305241) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_3507 |
Biomolecular Data
| Protein expression | Angiotensin converting enzyme (ACE), thrombospondin, cathepsin L, endostatin, interleukin-6 (interleukin 6, IL-6) |
|---|---|
| Antigen expression | CD31 +, vascular addressin +, CD45 (Ly5-T200) + |
| Tumorigenic | Yes, in syngeneic mice |
Handling
| Culture Medium | DMEM, w: 4.5 g/L Glucose, w: 4 mM L-Glutamine, w: 3.7 g/L NaHCO3, w: 1.0 mM Sodium pyruvate (Cytion article number 820300a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | Accutase |
| Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305241-300824 | Certificate of Analysis | 23. May. 2025 | 305241 |